Regulation of sensorimotor gating by interactions of dopamine and adenosine in the rat

Behavioural Pharmacology

Volumn 9, Issue 1, 1998, Pages 23-29

  Koch, M ^a   Hauber, W ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Acoustic startle response; Adenosine; Apomorphine; Dopamine; Prepulse inhibition; Rat; Schizophrenia

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 6 N CYCLOPENTYLADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; APOMORPHINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; RECEPTOR SUBTYPE; THEOPHYLLINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PREPULSE INHIBITION; RAT; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STARTLE REFLEX;

ACOUSTIC STIMULATION; ADENOSINE; ANIMALS; APOMORPHINE; DOPAMINE; DOPAMINE AGONISTS; MALE; PHENETHYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, PURINERGIC P1; STARTLE REACTION;

EID: 0031931817     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. 2+ channels by activation of adenosine A(1) receptors in rat striatal glutamatergic nerve terminals. Neuroset Lett 220:163-166.
2. Bakshi VP, Geyer MA, Taaid N, Swerdlow NR (1995). A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behav Pharmacol 6:801-809.
3. 2 adenosine receptor subtypes in locomotor activity and place conditioning in rats. Behav Pharmacol 7:373-383.
4. Braff DL, Geyer MA (1990). Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 47:181-188.
5. 3H]phenylxanthine. Proc Nat Acad Sci USA 77:5547-5551.
6. Campeau S, Davis M (1995). Prepulse inhibition of the acoustic startle reflex using visual and auditory prepulses: disruption by apomorphine. Psychopharmacology 117:267-274.
7. Collins MG, Hourani SMO (1993). Adenosine receptor subtypes. Trends in Pharmacol Sci 14:360-366.
8. Ferré S, Fuxe K, von Euler G, Johansson B, Fredholm BB (1992). Adenosine-dopamine interactions in the brain. Neuroscience 51:501-512.
9. 2 receptors in the ventral striatopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63:765-773.
10. 1 receptor-mediated mechanisms. Eur J Neurosci 8:1545-1553.
11. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997). Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends in Neurosci 20:482-487.
12. 2A receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. NeuroReport 8:1515-1518.
13. 2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia. Psychopharmacology 115:447-453.
14. Hoffman HS, Ison JR (1980). Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 87:175-189.
15. Hoffman DC, Donovan H, Cassella JV (1993). The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology 111:339-344.
16. Jarvis MF (1988). Autoradiographic Localization and Characterization of Brain Adenosine Receptor Subtypes. New York: Alan R. Liss.
17. Koch M, Schnitzler H-U (1997). The acoustic startle response in rats - circuits mediating evocation, inhibition and potentiation. Behav Brain Res 89:35-49.
18. Kretschmer BD, Koch M (1997a). Role of the strychnine-insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: a behavioral and microdialysis study. Psychopharmacology 130:131-138.
19. Kretschmer BD, Koch M (1997b). The ventral pallidum mediates disruption of prepulse inhibition of startle induced by dopamine agonists, but not by NMDA antagonists. Society for Neuroscience Abstracts 23:1281.
20. Lieberman JA, Koreen AR (1993). Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 19:371-429.
21. 2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 212:53.
22. 2a receptors. Trends in Pharmacol Sci 17:364-372.
23. 2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia. Neuropsychopharmacology 3:211-218.
24. Reijmers LGJR, Vanderheyden PML, Peeters BWMM (1995). Changes in prepulse inhibition after local administration of NMDA receptor ligands in the core region of the rat nucleus accumbens. Eur J Pharmacol 272:131-138.
25. Schwarzkopf SB, Bruno JP, Mitra T (1993). Effects of haloperidol and SCH 23390 on acoustic startle and prepulse inhibition under basal and stimulated conditions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 17:1023-1036.
26. Swerdlow NR, Geyer MA (1993). Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem and Behav 44:741-744.
27. Swerdlow NR, Braff DL, Masten VL, Geyer MA (1990). Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens. Psychopharmacology 101:414-420.
28. Swerdlow NR, Caine SB, Braff DL, Geyer MA (1992). The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications. Journal of Psychopharmacology 6:176-190.
29. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiat 51:139-154.
30. Wan F-J, Swerdlow NR (1996). Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions. Brain Res 722:168-176.
31. 2 interactions regulate prepulse inhibition in rats? Neuropsychopharmacology 14:265-274.
32. Williams M (1993). Purinergic drugs: opportunities in the 1990s. Drug Development Research 28:438.